We talked to Joseph Pesek (Professor Emeritus, San José State University, CA, USA) about his research developing novel stationary phases. Joe told us what which stationary phases he’s excited to see develop and gave us some tips for best practice.
In this podcast, we talk to Vibhor Gupta (Absorption Systems; PA, USA) about the importance of robust, reliable and accurate potency assays for cell and gene therapy products.
In this podcast, Szabolcs Szarka (Senior Scientist at LGC; Cambridgeshire, UK) discusses his use of HRMS and the benefits and challenges he has encountered in the field of pharmaceutical R&D and drug discovery. He also closes by offering his opinion on what he hopes the future may hold.
In this podcast we discuss the challenges faced by the modern bioanalyst and some of the innovative solutions that have been put into practice by scientists at Alturas Analytics (ID, USA).
In this interview, David Harris (Charles River Laboratories; NC, USA) discusses the current global landscape for cell therapy, associated safety concerns and challenges, and preclinical animal models that are used to evaluate cellular therapies.
Discover more about the development of CAR-T cell therapies, their bioanalytical challenges and specialized antibody reagents that can be ustilized to overcome these in this interview with Michael Schwenkert (Bio-Rad Laboratories; Germany).
Find out more about the role of exosomes in flow cytometry studies and future pharmacological developments in this interview with Joyce Slusser (KCAS; KS, USA).
Find out more about current challenges and recent developments in seen in the field of flow cytometry in this interview with Clara Brando and Ted Baginski (Eurofins; MO, USA).
Find out more about the challenges associated with gene therapy and what the future may hold for the field in this interview with Hugh Davis (Frontage Laboratories; PA, USA).
Find out more about the challenges associated with CAR-T cell immunotherapies and what the future may hold for the field in this interview with Marco Ruella.